Antisense Technology
"Treatment of Philadelphia Leukemia in Severe Combined Immunodeficient Mice by Combination of Cyclophosphamide and bcr/abl Antisense Oligodeoxynucleotides."
Published in Gene Therapy Weekly, February 24th, 1997
According to the authors' abstract of an article published in Journal of the National Cancer Institute, "Background: Philadelphia(1) cells are human chronic myelogenous leukemia (CML) cells that contain the BCR/ABL oncogene (a fusion of the BCR and ABL genes). Selective eradication of these cells in vitro can be achieved by combined treatment with antisense phosphorothioate oligodeoxynucleotides ([S]ODNs) specifically targeted to this oncogene (bcr/abl [S]ODNs) and a suboptimal (for use as a single agent) dose of mafosfamide (the in vitro active form of cyclophosphamide). Purpose: We evaluated the ability of bcr/abl antisense [S]ODNs, alone or subsequent to treatment...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (1997-02-24)
More Articles from Gene Therapy Weekly
- Gene Delivery
Improved Cationic Lipid Formulations Increase Efficiency, Physical Stability - Cardiovascular
Adv-Mediated Transfer of hsp70i Protects Against Ischemia - AIDS Therapies (Clinical Trials)
GEM 91 Moves Into Confirmatory Trial in Advanced HIV Patients - Cancer Gene Therapy
p53 Trials Expanded to Europe and Japan - Cancer Gene Therapy (Chemokines)
MIP-1(alpha) Gene Transfer Reduced Tumorigenicity and Induced Protective Immunity - Drug Development
Isis Pharmaceuticals Touts New Drug Therapies - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
